tbuckley/cabot-search huggingface dataset:
AB1652 THE PRESENCE OF DISEASE-SPECIFIC ANTIBODIES IN THE ABSENCE OF AN INFLAMMATORY RHEUMATIC DISEASE
Authors: T. Hoffmann, L. Wolff, P. Oelzner, G. Wolf, A. Pfeil
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Inflammatory rheumatic disease (IRD) are characterized by the appearance of a specific clinic, the presence of findings in immunological laboratory and imaging. Some patients presented specific IRD autoantibodies without a clinical manifestation of IRD. <h3>Objectives</h3> The objective of this study was to evaluate the frequency of disease-specific autoantibodies in patients with absence of clinical IRD manifestation. <h3>Methods</h3> The study included an analysis of 3793 Caucasian patients from a department of rheumatology localized at a university hospital in Europe specified for screening in IRD between 2015 and 2020. All patients revealed a standardized clinical examination and diagnostic procedure including immunological laboratory and imaging. Biopsies were performed when clinically indicated. Especially autoantibodies for rheumatoid arthritis (rheumatic factor [RF], anti-citrullinated peptide antibodies [ACPA]), connective tissue disease (antinuclear antibodies immunofluorescence test [ANA IFT] and extractable nuclear antibodies [ENA]), vasculitis (anti neutrophil cytoplasmatic antibodies [ANCA]) and myositis (myositis blot) were included. <h3>Results</h3> IRD was diagnosed in 1534 patients (40.4%) with the following distribution: 21.2% (n=325) rheumatoid arthritis, 22.8% (n=350) connective tissue disease, 6.5% (n=100) vasculitis and 2.3% (n=35) myositis. IRD was excluded in 762 patients (20.1%). 39.5% (n=1497) of the patients without a clinical manifestation of IRD presented a disease-specific autoantibody. 94.3% (n=1412). In detail, ANA IFT (≥1:80) with the different stages: 1:80 48.9% (n=691), 1:160 27.2% (n=384), 1:320 12.3% (n=174), 1:640 5.2% (n=73), 1:1280 4.4% (n=62), &gt;1:1280 2.0% (n=28), extractable nuclear antibodies 14.0% (n=208), RF and/or ACPA 16.8% (n=252), c-/p-ANCA 1.9% (n=29) and myositis autoantibodies 1.8% (n=27). The mean age of the Non-IRD patients was 52.2 ± 15.1 years, with 398 (26,6%) male and 1099 (73,4%) female patients. Both gender and age were significant different to the IRD group (p&lt;0.001). <h3>Conclusion</h3> The study highlighted that in screening of IRD 40 % of the patients presented IRD associated autoantibodies without a clinical manifestation of IRD. As already known, the isolated presence of disease-specific autoantibodies cannot confirm IRD. In this case, systematic and standardized organ screening is indispensable, to evaluate the clinical significance of the autoantibody. A clinical follow-up examination should be performed, especially if there is a change in symptoms or clinical suspicion of a possible organ manifestation of IRD. <h3>References</h3> N/A. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1707 FACTORS ASSOCIATED WITH SEDENTARY BEHAVIOR IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASE
Authors: S. Bahloul, H. Rkain, S. Ez-Zaoui, F. El Joumani, F. Kronbi, R. Honsali, S. Farih, I. Bensaghir, C. Nouri, T. Latifa, H. H. Najia, F. Allali
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background:</h3> <h3>Objectives</h3> To determine factors related to sedentary behavior in patients with a chronic inflammatory rheumatic disease(CIRD). <h3>Methods</h3> We conducted a cross-sectional study of 140 patients (mean age of 47.1 years, 68% females) affected by CIRD (Rheumatoid arthritis 56.4%, ankylosing spondylarthritis 32.1%, psoriatic arthritis 8.6% and juvenile idiopathic arthritis 2.9%). information on patients and disease characteristics were collected. Physical activity was measured objectively using the short version of the IPAQ questionnaire (International Physical Activity Questionnaire) for 7 consecutive days. Activity levels were subdivided into low physical activity and moderate to vigorous physical activity. We analyzed factors associated with sedentary behaviors. <h3>Results</h3> IPAQ Average was 413 (0.760) MET-min/week. The sedentary behavior was noted in 75.2% of patients. Table 1 summarizes factors associated with sedentary behavior in patients with chronic inflammatory rheumatic disease. <h3>Conclusion</h3> Sedentary behavior is very prevalent among CIRD patients. Awareness-raising actions on the importance of physical activity in CIRDs should be a priority for women and people with reduced mobility. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1692 A NEW, RELIABLE AND PRECISE HIGH-THROUGHPUT SERUM CALPROTECTIN ASSAY TO ASSESS THE INFLAMMATORY STATUS OF PATIENTS
Authors: A. Melone, D. Vogt, A. Ohmann, J. Afonso, C. Moniz, D. Guschin, C. B. Gerhold, T. Schuster
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Serum calprotectin (sCAL) is a promising biomarker to detect the inflammatory status of patients in rheumatoid arthritis, juvenile idiopathic arthritis and systemic onset juvenile idiopathic arthritis diseases. Serum calprotectin can be a useful tool to monitor disease activity and predict treatment response in these patients. <h3>Objectives</h3> The aim of this work was to evaluate the analytical performance of a new sCAL turbidimetric assay, a high throughput test on clinical chemistry analyzers, to determine calprotectin levels in serum. <h3>Methods</h3> CLSI guidelines (CLSI C28-A3, EP05-A3, EP07-A3, and EP09-A3) were used to establish sCAL turbidimetric assay characteristics.111 samples were measured with 3 lots over 3 days and compared to another commercially available assay. <h3>Results</h3> The assay presented an analytical measuring range from 0.23 to 15 µg/mL, extended to 225 µg/mL with an additional dilution in an automated rerun on a clinical chemistry analyzer. Reference limits of 1.77 and 1.10 µg/mL were obtained with 160 self-declared healthy adults (m/w) aged 18 to 83 years when sampled either in native tube or tube with gel separator and processed within 3.4 hours after collection respectively. The method is precise, reliable and suitable for routine use, with a within-laboratory precision up to 5.1% and a reproducibility up to 11.1%. No interference was shown with tested concentrations of oral and injectable pharmaceuticals. Hemolyzed samples are not recommended. A method comparison with another commercial assay presented a good agreement with a bias of 2.45% (Bland-Altman) and a slope of 1.16 (Passing Bablok). <h3>Conclusion</h3> The new sCAL turbidimetric assay is a high throughput quantitative method performed on clinical chemistry analyzers to reliably and precisely assess the inflammatory status of patients. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Anna Melone Employee of: Author is employee of BÜHLMANN Laboratories AG, Dominik Vogt Employee of: Author is employee of BÜHLMANN Laboratories AG, Alexander Ohmann Employee of: Author is employee of BÜHLMANN Laboratories AG, Joana Afonso Employee of: Author is employee of BÜHLMANN Laboratories AG, Clara Moniz Employee of: Author is employee of BÜHLMANN Laboratories AG, Dmitrii Guschin Employee of: Author is employee of BÜHLMANN Laboratories AG, Christian-Benedikt Gerhold Employee of: Author is employee of BÜHLMANN Laboratories AG, Thomas Schuster Employee of: Author is employee of BÜHLMANN Laboratories AG.
AB1746-PARE THE CORRELATION OF FUNCTIONAL DISABILITY AND MENTAL DISORDERS IN PATIENTS TREATED FOR SPONDYLODISCITIS
Authors: Y. Mabrouk, L. Rouached, A. Ben Ammou, Z. Syrine, S. Akremi, S. Larbi, A. Ben Abid, M. Ben Salah
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Although it still remains a rare disease, spondylodiscitis has been on the rise in the past decades. Early diagnosis can be difficult, but Improved diagnostic techniques and modern treatments have reduced patient mortality. However, studies reporting the outcome of spondylodiscitis are scarce. <h3>Objectives</h3> To assess the influence of functional impairment on mental health in patients surgically treated for spondylodiscitis. <h3>Methods</h3> A prospective study was carried out on patients treated for spondylodiscitis over a two-year period at a single spine center. The socio-demographic data, clinical, radiological, biological and therapeutic parameters were collected. A questionnaire was conducted on all eligible patients with the hospital anxiety and depression scale: HAD and the Oswestry disability index: ODI. All data was collected after patient consent and was analyzed using the SPSS statistical package. <h3>Results</h3> Thirty –six patients were selected for the study, with a sex ratio (M/ F) of 1.57. The average age was 56 [18_73]. 22% had comorbidities: 16% diabetes, 6% psychiatric illnesses. 22% were smokers. 72% had a sedentary lifestyle. Mycobacterium tuberculosis was the predominant pathogen(33%) followed by Staphylococcus aureus (22%). Culture was negative in 5 % of patients. Of these, 33% patients received antituberculosis medical treatment. The lumbar spine was the most frequent level of spinal focus (55%). 22% of patients had more than one focus in the spine. 54% of patients had neurological impairment: paraplegia 33%, sensory deficit 11% and confusion 6%. All patients were treated surgically: 32% internal corset, 31% fixation, 20% arthrodesis, 11% corporectomy, 6% laminectomy. The mortality rate was 6%. Average HAD score was 13.3[0-40]: depressive dimension: 6.6[0-20], anxiety dimension 6.8[0-20], with scores indicating very likely depression and anxiety in 22% and 25 % of patients, respectively. Mild, moderate and severe functional disability was noted in 44%, 18% and 6%, respectively, according to the ODI score. In our series, there were positive correlations between gender, VAS (visual analog scale) spinal pain and ODI score: p=0.025 and p=0.007, respectively. In the same way, there were positive correlations between the ODI score and the HAD depression dimension (p=0.001) and the anxiety one (p=0.001). <h3>Conclusion</h3> Two years after surgery, patients treated for spondylodiscitis have significant functional disability. Anxiety and depression, mainly due to interaction with the disability level, are two comorbidities to consider in spondylodiscitis. Screening and psychological support is then necessary. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1668 RESPIRATORY INFECTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS, PRIMARY AND SECONDARY AFS BEFORE AND AFTER VACCINATION WITH 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE
Authors: G. Koilubaeva, G. Tarasova, B. Belov, A. Bolotbekova, G. Syunbai K, A. Turatbekova
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Infections are one of the main causes of morbidity and mortality in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Pneumococcal vaccination can significantly reduce the number of serious respiratory infections in this group of patients. <h3>Objectives</h3> To analyze the frequency of respiratory infections in systemic lupus erythematosus (SLE), secondary and primary antiphospholipid syndrome (AFS) before and after vaccination with 23-valent polysaccharide pneumococcal vaccine (PPV-23). <h3>Methods</h3> 91 patients were included in the study, 78 of them with SLE, including 18 with secondary AFS; 13 patients with primary AFS. The follow-up period was 12 months. All patients with SLE and secondary AFS received immunosuppressive therapy, including 29 anti-B-cell therapy. With primary AFS, 6 patients received immunosuppressive therapy, including 1- rituximab. <h3>Results:</h3> All LRTI were more common in SLE (48.3%, 27.8%, 11.8%, respectively), mainly due to the more frequent development of pneumonia (Pn) (20%, 11%, 7.7%, respectively). After vaccination, the number of pneumonias decreased from 15 (16.5%) to 4 (4.4%) and were registered only in patients with SLE, p=0.01. These were not severe pneumonia, did not require hospitalization; in all cases there were predisposing factors (anti-B-cell therapy with the absence of an adequate vaccine response - 3, interstitial lung disease (ISL) - 1). Before vaccination, among ENT infections, sinusitis was more common with SLE than with SLE + secondary APS (16.7%, 8.3%, respectively), with primary APS it was not detected.After vaccination, infections of ENT organs in patients with primary and secondary AFS were absent, with SLE there was a significant decrease (from 30% to 10%). With primary AFS, respiratory diseases have not been registered after vaccination. <h3>Conclusion</h3> The clear clinical efficacy of PPV-23 in patients with SLE and AFS has been demonstrated. In primary AFS, fewer respiratory infections and their absence after vaccination are naturally explained by less aggressive immunosuppressive therapy. A possible reason for the lower number of INDO in secondary AFS, in comparison with SLE without AFS, may be the absence of ISL in these patients. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1781-HPR PERFORMANCE OF A NURSE-LED INTERVIEW FOR MALIGNANCY SCREENING AND ALERTING PHYSICIAN PROGRAM
Authors: S. Tamaki, S. Fukui, M. Suda, H. Tamaki, M. Okada
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Malignancy is one of the leading causes of death in patients with rheumatoid arthritis (RA). While there has been a debate about whether or not biological disease-modifying antirheumatic drugs (bDMARDs) increase cancer development in RA patients, these patients should be screened appropriately for their malignancies. However, there has been limited data about the method to increase malignancy screening. <h3>Objectives</h3> We implemented a nurse-led malignancy screening and alerting physician program into our daily clinical practice. The aim of this study is to evaluate the performance of this program. <h3>Methods</h3> Our program included patients with RA treated with intravenous biological DMARDs between September 2015 and October 2020. We first created a list of the required malignancy screening based on the patient's gender and age (Figure 1). Nurses interviewed the patients during the administration of bDMARDs to assess if they were appropriately screened for malignancies as required and thereafter provided education about the importance of malignancy screening. Nurses recorded the patient's malignancy screening status and alerted physicians by sharing the results if the patient needed additional screenings. This program was periodically repeated once a year. We assessed the difference in the proportions of completed per required screening between repeated assessment time points. <h3>Results</h3> A total of 154 patients were included in the analyses. The mean (standard deviation) age was 64.6 (13.2) at the first screening, and 113 (73.4%) were female. Ninety-three, forty-five, and fourteen patients underwent 2<sup>nd</sup>, 3<sup>rd</sup>, and 4<sup>th</sup> interviews, respectively. Repeating this program numerically increased the proportion of conducted malignancy screenings per required screening. (58.6%, 66.5%, 60.6%, and 73.1% at the 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>, and 4<sup>th</sup> interview, respectively) (Table 1). In addition, several patients understood, for the first time, the importance of malignancy screening during this interview with nurses. <h3>Conclusion</h3> Implementing a nurse-led interview for malignancy screening and alerting physician program numerically increased the screening of malignancy in RA patients treated with bDMARDs. This multi-disciplinary cooperation can potentially improve the quality of healthcare for patients with RA. <h3>Reference</h3> [1]Pundole X, Suarez-Almazor ME. Cancer and Rheumatoid Arthritis. Rheum Dis Clin North Am. 2020 Aug;46(3):445-462. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1762-HPR CAN PATIENT-REPORTED OUTCOMES BE USED TO TRIAGE PATIENTS WITH ANKYLOSING SPONDYLITIS TO MOBILITY MEASUREMENTS OR TESTING OF C-REACTIVE PROTEIN?
Authors: C. Fougman Mccarthy, K. Hörnberg, T. Weitoft, M. Björklund, B. Sundström
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Patients with Ankylosing Spondylitis are assessed by healthcare with regular controls of mobility and disease activity. If these controls can be replaced by valid patient-reported index, it would unburden both patients and healthcare. <h3>Objectives</h3> In this study we analysed associations between healthcare measured mobility and disease activity and patient-reported disease activity, physical function and well-being in patients with AS. <h3>Methods</h3> This register-based cross-sectional study used data from 1541 visits (of which 1093 visits were men and 448 women) in the Swedish Rheumatology Quality Register. Variables for healthcare measured spinal mobility and disease activity were Ankylosing Spondylitis Metrology Index (BASMI) and C-Reactive Protein (CRP). Variables for patient-reported disease activity, physical function and well-being were Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Global Score (BAS-G). First, associations were tested with Pearsons correlation. Secondly, discriminative ability to identify subnormal BASMI, or CRP [defined as below the 2.5th percentile of healthy individuals, and &gt;3, respectively [1,2], was determined by means of receiver operating characteristic (ROC) curve analysis for variables with coefficients r &gt;0.4. <h3>Results</h3> Associations with r &gt;0.4 was found only between BASMI and BASFI (r=0.49), resulting with an area under the curve (AUC) of 0.74 (95% CI; 0.72- 0.76) in the ROC analyses. Among the subquestions of BASMI/BASFI, the highest association was seen between measured cervical rotation and the self-assessed ability to look over shoulder (r=-0.69), resulting in AUC of 0.85 (95% CI; 0.83-0.88) in the corresponding ROC analyses, using cervical rotation below 2.5th percentile of healthy individuals as discrimination value. <h3>Conclusion</h3> A significant association with r &gt;0.4 was seen between BASMI and BASFI. The resulting AUC of 0.74 between BASMI and BASFI, and 0.85 between measured cervical rotation and self-assessed ability to look over shoulder, can be deemed as acceptable and excellent, respectively [3]. BASFI and its sub-questions may therefore be of interest for further evaluation if they could be used for screening and triaging patients to spinal mobility measurements with BASMI. Neither of the self-reported indices associated with CRP to any higher degree (r &lt;0.4). <h3>References</h3> [1]Ramiro S, et al. Ann Rheum Dis 2015;74:1218–1224. [2]Pearson, TA, et al. Circulation 2003, 107, 499-511 [3]Mandrekar JN. J Thorac Oncol. 2010;5: 1315–1316 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1723-PARE A CANADIAN PATIENT-DRIVEN SURVEY TO HIGHLIGHT WHICH PREDNISONE-RELATED SIDE EFFECTS MATTER THE MOST
Authors: G. K. Yardimci, C. Pagnoux, J. Stewart
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Management of vasculitis has evolved for the last two decades; however, glucocorticoids (GC) remain the cornerstone of the treatment. Although the side effects (SE) of prednisone are well recognized by the clinicians, their importance for vasculitis patients has not been investigated extensively. <h3>Objectives</h3> We conducted a patient centered survey to identify the relative importance of GC-associated SE among patients with vasculitis. <h3>Methods</h3> An online questionnaire surveyed patients registered with the Vasculitis Foundation Canada about their experience and SE of GC. The questionnaire consisted of demographics and diagnosis, 5 questions about GC dose and duration, 21 about specific SE (with a rating of some pre-specified SE), 4 about knowledge and perception about possible alternatives to prednisone. <h3>Results</h3> 97 patients (53 GPA/MPA,44 other vasculitides) completed the survey. The mean age was 56.9 years, and disease duration was 10.6 years. Mean duration of GC use was 62.7±83.7months, and 49.5% of patients were still on GC (daily dose, 8.4±6.2mg). All the patients reported ≥1GC-related SE, with 67.1% of them reporting having had ≥11/19 SE of interest. The SE reported most frequently included mood change in 93 (95.8%) patients, insomnia and weight gain in 91 (93.8%), and body disfiguration in 89 (91.7%) patients (Table 1). Among ranked SEs, acne was ranked with the lowest score, whereas moon face/torso hump had the highest ranking, just above weight gain, insomnia and impaired quality of life (Figure 1). Half of the GPA/MPA patients and one-third of the others have heard about avacopan, and 68% of patients (similarly in both groups) stated they would prefer being the first to take a very new medication, such as avacopan, instead of prednisone. <h3>Conclusion</h3> This patient-driven survey emphasizes the patient experience and perspectives on GC-related SE, with weights given to some SE that may differ from those given by physicians. GC toxicity indexes should reflect this, and alternative treatment options should be developed. <h3>Acknowledgements</h3> The authors would like to thank the network of Vasculitis Foundation Canada patients who participated in this survey. <h3>Disclosure of Interests</h3> None Declared.